Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from first dose of study treatment through ~14 (±4) days after the final dose
Summary
This trial is testing CY6463, a new drug, in people aged 60+ with Alzheimer's and cardiovascular issues. The drug aims to improve brain function by enhancing a key signaling pathway. Participants will take the drug regularly for a few months. CY6463 has shown potential in reducing inflammation and improving brain function in neurodegenerative diseases.
Eligible Conditions
- Mixed Dementia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from first dose of study treatment through ~14 (±4) days after the final dose
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from first dose of study treatment through ~14 (±4) days after the final dose
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of Treatment-emergent Adverse Events (TEAEs) From Study Drug Initiation Through Follow-up
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: CY6463Experimental Treatment1 Intervention
CY6463 once daily (QD) for approximately 87 sequential days.
Group II: PlaceboPlacebo Group1 Intervention
Placebo QD for approximately 87 sequential days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CY6463
2021
Completed Phase 1
~50
Find a Location
Who is running the clinical trial?
Cyclerion TherapeuticsLead Sponsor
17 Previous Clinical Trials
885 Total Patients Enrolled
Tisento TherapeuticsLead Sponsor
5 Previous Clinical Trials
234 Total Patients Enrolled
Study DirectorStudy DirectorTisento Therapeutics
1,276 Previous Clinical Trials
499,265 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger